The use of histotripsy as intratumoral immunotherapy beyond tissue ablation—the rationale for exploring the immune effects of histotripsy

Abstract

Mechanical high-intensity focused ultrasound (M-HIFU), which includes histotripsy, is a non-ionizing, non-thermal ablation technology that can be delivered by noninvasive methods. Because acoustic cavitation is the primary mechanism of tissue disruption, histotripsy is distinct from the conventional HIFU techniques resulting in hyperthermia and thermal injury. Phase I human trials have shown the initial safety and efficacy of histotripsy in treating patients with malignant liver tumors. In addition to tissue ablation, a promising benefit of M-HIFU has been stimulating a local and systemic antitumor immune response in preclinical models and potentially in the Phase I trial. Preclinical studies combining systemic immune therapies appear promising, but clinical studies of combinations have been complicated by systemic toxicities. Consequently, combining M-HIFU with systemic immunotherapy has been demonstrated in preclinical models and may be testing in future clinical studies. An additional alternative is to combine intratumoral M-HIFU and immunotherapy using microcatheter-placed devices to deliver both M-HIFU and immunotherapy intratumorally. The promise of M-HIFU as a component of anti-cancer therapy is promising, but as forms of HIFU are tested in preclinical and clinical studies, investigators should report not only the parameters of the energy delivered but also details of the preclinical models to enable analysis of the immune responses. Ultimately, as clinical trials continue, clinical responses and immune analysis of patients undergoing M-HIFU including forms of histotripsy will provide opportunities to optimize clinical responses and to optimize application and scheduling of M-HIFU in the context of the multi-modality care of the cancer patient.

Keywords:

• Mechanical high-intensity focused ultrasound (M-HIFU)
• histotripsy
• immunotherapy

Disclosure statement

HKL is co-founder and equity holder in SONOKINE Bioscience, YZ is a co-founder and equity holder in SONOKINE Bioscience, XJ is a co-founder and equity holder in SONOKINE Bioscience, PZ is an equity holder in SONOKINE Bioscience.

Data availability statement

Raw data were generated at Duke University and North Carolina State University. Derived data supporting the findings of this study are available from the corresponding author [HKL] on request.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.